

Special Issue

Endometrial Cancer—from Diagnosis to Management

Message from the Guest Editors

Endometrial cancer (EC) is the sixth most common cancer to affect women worldwide and the most prevalent gynecologic malignancy in American women. Although EC is curable when found and treated early, the 5-year overall survival rate for stage IV EC is only 15–17%. In recent years, EC's incidence and mortality rates have been increasing. According to the American Cancer Society, about 67,880 new cases are expected in 2024, the management of which requires a deeper understanding of the disease pathophysiology and an advanced discovery of strategies for early diagnosis. Thus, this Special Issue aims to discuss diagnosis, novel prognosis biomarkers, and recent advancements in disease management. We welcome for submission to this Special Issue original research articles and reviews. Research may include basic, translational, and clinical studies. We look forward to receiving your contributions.

Guest Editors

Dr. Mingxin Shi

School of Molecular Biosciences, Washington State University, Pullman, WA, USA

Dr. Xiang Zhao

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA

Deadline for manuscript submissions

closed (31 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/210938

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)